Corrections to “PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab”
Titel:
Corrections to “PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab”
Auteur:
Loibl, S. Majewski, I. Guarneri, V. Nekljudova, V. Holmes, E. Bria, E. Denkert, C. Schem, C. Sotiriou, C. Loi, S. Untch, M. Conte, P. Bernards, R. Piccart, M. von Minckwitz, G. Baselga, J.